To access this element change to forms mode OFF
Grant Award View - GA52665
Therapeutic targeting of a novel self-renewal signalling in leukaemia...
GA ID:
GA52665
Agency:
Cancer Australia
Approval Date:
5-Apr-2019
Publish Date:
3-Jul-2019
Category:
Cancer
Grant Term:
30-Jun-2019 to 29-Jun-2022
Value (AUD):
$300,000.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
CA 18/19 Improved cancer control
Grant Program:
2018 Priority-driven Collaborative Cancer Research Scheme
Grant Activity:
Therapeutic targeting of a novel self-renewal signalling in leukaemia stem cells
Purpose:
Acute myeloid leukaemia (AML) is a fatal form of blood cancer in children. The survival of AML patients remains poor due to the return of disease after chemotherapy (relapse). Leukaemia stem cells (LSCs) are the major cause of relapse and we are studying how to eradicate them without harming healthy cells. This project will develop a novel LSC-targeted therapy with minimal side effects and toxicity that will improve the dismal outcome of childhood AML.
GO ID:
GO Title:
2018 PdCCRS Project Grants for funding commencing 2019
Internal Reference ID:
2018 PdCCRS
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
No
Confidentiality - Outputs:
No
Grant Recipient Details
Recipient Name:
University of New South Wales
Recipient ABN:
57 195 873 179
Grant Recipient Location
Suburb:
Kensington
Town/City:
Sydney
Postcode:
2052
State/Territory:
NSW
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
National
Postcode:
Multiple
Country:
AUSTRALIA